NantHealth, Inc. (NHIQ) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören NantHealth, Inc. (NHIQ), 0 değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 52/100 puan alıyor.
Son analiz: 16 Mar 2026NantHealth, Inc. (NHIQ) Sağlık ve Boru Hattı Genel Bakışı
NantHealth, Inc. delivers SaaS-based clinical decision support and data solutions to healthcare providers and payers, focusing on oncology and network monitoring. Their Eviti platform and NaviNet solutions aim to improve care coordination and streamline administrative processes within the complex healthcare ecosystem, operating primarily in the US, Canada, and the UK.
Yatırım Tezi
NantHealth, Inc. operates in the healthcare IT sector, which is experiencing growth due to the increasing need for efficient data management and care coordination. The company's Eviti platform and NaviNet solutions address these needs, particularly in the oncology space. However, with a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance raises concerns. A gross margin of 57.0% indicates some operational efficiency, but a profit margin of -101.2% suggests significant challenges in achieving profitability. Key value drivers include expanding the adoption of Eviti and NaviNet solutions, securing new partnerships with payers and providers, and demonstrating improved financial performance. The high beta of -5.74 suggests high volatility. Investors should carefully consider the company's financial stability and growth prospects before investing.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- Gross Margin of 57.0% demonstrates the potential for profitability if operating expenses are managed effectively.
- Profit Margin of -101.2% signals significant challenges in achieving profitability and requires close monitoring.
- Beta of -5.74 suggests the stock price moves inversely and more drastically than the market, indicating high volatility.
- Offers SaaS based solutions - clinical decision support and network monitoring - which can lead to recurring revenue streams.
Rakipler & Benzerleri
Güçlü Yönler
- Comprehensive Eviti platform for cancer treatment decision support.
- NaviNet platform for streamlined payer-provider communication.
- SaaS-based business model providing recurring revenue.
- Established presence in the US, Canada, and the UK.
Zayıflıklar
- Negative profit margin indicating financial challenges.
- High beta suggesting high stock price volatility.
- Limited market capitalization compared to larger competitors.
- Dependence on NantWorks, LLC for resources and support.
Katalizörler
- Ongoing: Expansion of the Eviti platform to cover additional cancer types and treatment modalities.
- Ongoing: Strategic partnerships with major health insurance companies to integrate NaviNet.
- Upcoming: Potential geographic expansion into European markets.
- Upcoming: Development and launch of AI-powered analytics for the Quadris data solution.
- Ongoing: Integration of Eviti and NaviNet solutions with telehealth platforms.
Riskler
- Ongoing: Intense competition from larger healthcare IT companies.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Potential: Data security and privacy concerns.
- Potential: Technological obsolescence.
- Ongoing: Negative profit margin and financial challenges.
Büyüme Fırsatları
- Expansion of Eviti Platform: NantHealth has the opportunity to expand the capabilities of its Eviti platform to cover a broader range of cancer types and treatment modalities. By incorporating the latest research and clinical guidelines, Eviti can become an even more valuable tool for oncologists, driving increased adoption and revenue growth. The market for oncology clinical decision support systems is projected to reach $1.5 billion by 2028, presenting a significant opportunity for NantHealth to capture a larger share.
- Strategic Partnerships with Payers: Collaborating with major health insurance companies to integrate NaviNet into their existing systems can streamline pre-authorization processes and improve communication with providers. This can lead to increased efficiency and cost savings for payers, making NaviNet an attractive solution. The market for payer-provider communication platforms is estimated at $2.2 billion, offering substantial growth potential for NantHealth through strategic partnerships.
- Geographic Expansion into Europe: Expanding its operations into European markets, where healthcare systems are increasingly focused on digitization and value-based care, represents a significant growth opportunity for NantHealth. By adapting its Eviti and NaviNet solutions to meet the specific needs of European healthcare providers and payers, NantHealth can tap into a new revenue stream. The European healthcare IT market is projected to reach $80 billion by 2027.
- Development of AI-Powered Analytics: Incorporating artificial intelligence (AI) and machine learning (ML) into its Quadris data solution can enable NantHealth to provide more advanced analytics and insights to healthcare providers and payers. This can help them identify trends, predict outcomes, and optimize treatment strategies. The market for AI in healthcare is projected to reach $45 billion by 2026, presenting a significant opportunity for NantHealth to leverage its data assets and expertise.
- Integration with Telehealth Platforms: Integrating its Eviti and NaviNet solutions with telehealth platforms can enable NantHealth to extend its reach and provide its services to a wider range of patients and providers. This can be particularly valuable in rural areas and underserved communities, where access to specialized healthcare services may be limited. The telehealth market is projected to reach $175 billion by 2026, offering a substantial growth opportunity for NantHealth through strategic integrations.
Fırsatlar
- Expansion of Eviti platform to cover more cancer types.
- Strategic partnerships with major health insurance companies.
- Geographic expansion into European markets.
- Development of AI-powered analytics for Quadris data solution.
Tehditler
- Intense competition from larger healthcare IT companies.
- Changes in healthcare regulations and reimbursement policies.
- Data security and privacy concerns.
- Potential for technological obsolescence.
Rekabet Avantajları
- Proprietary Technology: Eviti's comprehensive library of evidence-based treatment standards and protocols provides a competitive advantage.
- Established Relationships: Long-standing relationships with payers and providers create switching costs.
- Data Network Effects: The more users on the NaviNet platform, the more valuable it becomes for all participants.
NHIQ Hakkında
NantHealth, Inc., established in 2010 and headquartered in Morrisville, North Carolina, is a healthcare IT company operating in the United States, Canada, and the United Kingdom. As a subsidiary of NantWorks, LLC, NantHealth provides a suite of software and data solutions designed to improve healthcare delivery and administrative efficiency. The company's core offerings include the Eviti platform, a SaaS-based clinical decision support system that centralizes clinical content, treatment cost data from Medicare reimbursements, and treatment toxicity data. Eviti Connect leverages this platform to automate pre-authorization processes, assisting payers and providers in navigating the complexities of cancer care. Additionally, Eviti Advisor allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. NantHealth also offers NaviNet, a suite of SaaS-based solutions that streamline communication and consolidate information between payers and providers. NaviNet Open serves as a payer-provider collaboration platform, while NaviNet AllPayer provides eligibility, benefit, and claim status information to provider offices for commercial and government plans, including Medicare beneficiaries. Furthermore, NantHealth provides OpenNMS, an open-source network monitoring solution for enterprise-grade networks, and Quadris, a data solution that includes multi-data analysis, reporting, and professional services. Originally known as Nant Health, LLC, the company changed its name to NantHealth, Inc. in June 2016.
Ne Yaparlar
- Offers Eviti, a SaaS-based clinical decision support solution for cancer treatment.
- Provides Eviti Connect, automating pre-authorization for cancer care.
- Offers Eviti Advisor, giving physicians access to evidence-based treatment standards.
- Delivers NaviNet, a suite of SaaS solutions for payer-provider communication.
- Provides NaviNet Open, a platform for collaboration between health plans and providers.
- Offers NaviNet AllPayer, providing eligibility and claim status information.
- Provides OpenNMS, an open-source network monitoring solution.
- Offers Quadris, a data solution for multi-data analysis and reporting.
İş Modeli
- Software-as-a-Service (SaaS): Generates recurring revenue through subscriptions to its Eviti and NaviNet platforms.
- Data Solutions: Provides data analysis, reporting, and professional services through its Quadris solution.
- Platform Integration: Earns revenue by integrating its solutions with payer and provider systems.
Sektör Bağlamı
NantHealth, Inc. operates within the healthcare IT sector, a market driven by the increasing adoption of electronic health records (EHRs), the growing need for interoperability, and the rising demand for data analytics solutions. The industry is characterized by intense competition, with established players like ACHKF (Allscripts Healthcare Solutions) and ALDNF (Cerner Corporation) vying for market share. NantHealth's focus on oncology and payer-provider communication positions it within specific niches of this broader market. The healthcare IT market is projected to continue growing, fueled by government initiatives promoting healthcare digitization and the increasing prevalence of chronic diseases.
Kilit Müşteriler
- Healthcare Providers: Oncologists, hospitals, and clinics use Eviti to support treatment decisions.
- Health Insurance Companies: Payers use NaviNet to streamline communication and pre-authorization processes.
- Enterprise-Grade Networks: Organizations use OpenNMS for network monitoring.
Finansallar
Grafik & Bilgi
NantHealth, Inc. (NHIQ) hisse senedi fiyatı: Price data unavailable
Son Haberler
NHIQ için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
NHIQ için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
NHIQ için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, NHIQ'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Yönetim: Rao Haris Naseem FACC,
CEO
Rao Haris Naseem is the CEO of NantHealth, Inc. His background includes extensive experience in the healthcare sector, with a focus on clinical and technological innovation. He is a Fellow of the American College of Cardiology (FACC), indicating expertise in cardiovascular medicine. His leadership aims to drive the company's growth through strategic partnerships and technological advancements in healthcare IT. He is responsible for overseeing the company's operations and strategic direction.
Sicil: Since becoming CEO, Rao Haris Naseem has focused on expanding NantHealth's product offerings and strengthening its relationships with key stakeholders in the healthcare industry. Key achievements include enhancing the Eviti platform's capabilities and securing new partnerships with payers and providers. He has also overseen the development of AI-powered analytics for the Quadris data solution. His leadership is geared towards improving the company's financial performance and market position.
NHIQ OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that NantHealth, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may be subject to less regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and information.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited Liquidity: Lower trading volumes can make it difficult to buy or sell shares without significantly impacting the price.
- Information Scarcity: Lack of readily available financial information and regulatory oversight increases the risk of fraud or mismanagement.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volumes and speculative trading.
- Delisting Risk: The company may not meet the requirements for continued listing on the OTC market, leading to potential delisting.
- Penny Stock Rules: OTC stocks may be subject to penny stock rules, which impose additional restrictions and disclosure requirements on brokers.
- Verify the company's registration and regulatory filings with the SEC or other relevant authorities.
- Review the company's financial statements, if available, and assess its financial health and performance.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Consult with a qualified financial advisor before investing.
- Check for any legal or regulatory actions against the company or its management.
- Established Operations: NantHealth, Inc. has been in operation since 2010, indicating some level of stability.
- Subsidiary of NantWorks, LLC: Being a subsidiary of NantWorks, LLC provides some level of credibility.
- SaaS-Based Solutions: Offering SaaS-based solutions suggests a recurring revenue model.
- CEO with Relevant Experience: Rao Haris Naseem's background in healthcare and cardiology lends some credibility to the company's leadership.
NHIQ Hakkında Sıkça Sorulan Sorular
NHIQ için değerlendirilmesi gereken temel faktörler nelerdir?
NantHealth, Inc. (NHIQ) şu anda yapay zeka skoru 52/100, orta puanı gösteriyor. Temel güçlü yan: Comprehensive Eviti platform for cancer treatment decision support.. İzlenmesi gereken birincil risk: Ongoing: Intense competition from larger healthcare IT companies.. Bu bir finansal tavsiye değildir.
NHIQ MoonshotScore'u nedir?
NHIQ şu anda MoonshotScore'da 52/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
NHIQ verileri ne sıklıkla güncellenir?
NHIQ fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler NHIQ hakkında ne diyor?
NHIQ için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
NHIQ'a yatırım yapmanın riskleri nelerdir?
NHIQ için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Intense competition from larger healthcare IT companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
NHIQ'ın P/E oranı nedir?
NHIQ için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için NHIQ'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
NHIQ aşırı değerli mi, yoksa düşük değerli mi?
NantHealth, Inc. (NHIQ)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
NHIQ'ın temettü verimi nedir?
NantHealth, Inc. (NHIQ) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the most recent available information.
- AI analysis is pending and will provide further insights.